Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zetagen Therapeutics Inc. is engaged in the Biotechnology & Pharmaceuticals technology area. The company's prosecution profile includes 2 pending office actions. These actions are distributed across 2 distinct art units, which points to a diverse range of applications within the broader pharmaceutical field. Furthermore, the company is working with 2 distinct examiners, meaning that each pending matter is being handled by a different individual.
HAGOPIAN, CASEY SHEA is the busiest examiner for this portfolio, currently managing 1 pending office action. This examiner is responsible for a portion of the 2 pending office actions, while the other is handled by another distinct examiner. The separation of the workload into 2 distinct art units suggests that the prosecution strategy must be tailored to the specific standards of different examination groups. Managing the 2 distinct examiners requires a coordinated approach to address the unique requirements of HAGOPIAN, CASEY SHEA and the other examiner involved in the Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGOPIAN, CASEY SHEA | 1 | 54.4% | +33.3% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463056 | METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS | HAGOPIAN, CASEY SHEA | 15d |
| 18366439 | METHODS OF TREATING PROSTATE CANCER OR METASTASIZED PROSTATE CANCER | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18463056 | METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS | HAGOPIAN, CASEY SHEA | 1617 | DP | Final Rejection | 15d | Pending | Sep 07, 2023 |
| 18366439 | METHODS OF TREATING PROSTATE CANCER OR METASTASIZED PROSTATE CANCER | LEE, CHIHYI NMN | 1628 | §103DP | Non-Final OA | — | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial